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ABSTRACT
As a topical cancer immunotherapy, the toll-like receptor 7 ligand imiquimod 
activates tumor regression via stimulation of immune cell infiltration and cytotoxic 
responses. Imiquimod also exerts direct pro-apoptotic effects on tumor cells in 
vitro, but a role for these effects in imiquimod-induced tumor regression remains 
undefined. We previously demonstrated that cell lines derived from devil facial tumor 
disease (DFTD), a transmissible cancer threatening the survival of the Tasmanian 
devil (Sarcophilus harrisii), are sensitive to imiquimod-induced apoptosis. In this 
study, the pro-apoptotic effects of imiquimod in DFTD have been investigated using 
RNA-sequencing and label-free quantitative proteomics. This analysis revealed 
that changes to gene and protein expression in imiquimod treated DFTD cells are 
consistent with the onset of oxidative and endoplasmic reticulum stress responses, 
and subsequent activation of the unfolded protein response, autophagy, cell cycle 
arrest and apoptosis. Imiquimod also regulates the expression of oncogenic pathways, 
providing a direct mechanism by which this drug may increase tumor susceptibility 
to immune cytotoxicity in vivo. Our study has provided the first global analysis of 
imiquimod-induced effects in any tumor cell line. These findings have highlighted 
the potential of cell stress pathways as therapeutic targets in DFTD, and will allow 
for improved mechanistic use of imiquimod as a therapy in both the Tasmanian devil 
and human cancers.
INTRODUCTION
Imiquimod (R-837), an imidazoquinoline analogue 
of guanosine, is a potent immune modifier [1]. Primarily 
known as an agonist of the viral single stranded RNA 
sensor toll-like receptor 7 (TLR7), imiquimod has 
attracted interest in clinical immunotherapy trials for its 
anti-viral and anti-tumor properties [1–3]. Currently, it is 
approved by the FDA as a topical immunotherapy against 
external genital and perianal warts, actinic keratosis and 
superficial basal cell carcinoma [2]. Successful imiquimod 
immunotherapy against these and other lesions leads to 
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extensive immune infiltration and subsequent regression 
via TLR7-dependent cytotoxic mechanisms [4, 5]. TLR7 
is expressed at high levels by plasmacytoid dendritic 
cells (pDCs), which play key roles in the recruitment 
and activation of cytotoxic immune cells via cytokine 
and chemokine production [6]. Imiquimod-stimulated 
pDCs in mouse models can also directly suppress tumor 
growth and stimulate apoptosis through TLR7-dependent 
TNF-related apoptosis-inducing ligand (TRAIL) and 
granzyme B release [7, 8]. Imiquimod may also inhibit 
immune-regulatory pathways via antagonism of adenosine 
receptor signalling [9], and activate NLRP3-mediated 
inflammasome signalling via stimulation of ROS 
production [10]. This ability of imiquimod to act on the 
immune response at multiple levels could account for its 
success as an anti-cancer drug.
It has previously been found that imiquimod has 
direct effects on tumor cell function in vitro and in vivo. 
Studies in vitro revealed direct activation of intrinsic 
apoptosis in cell lines from a range of cancers including 
malignant melanoma, basal cell carcinoma, squamous cell 
carcinoma, gastric cancer and endometrial cancer [11–15]. 
These apoptotic pathways were activated via mechanisms 
involving oxidative and endoplasmic reticulum (ER) 
stress, and regulation of the BCL2 family of proteins 
[14–19]. Autophagic pathways have also been implicated 
in this process and may contribute to imiquimod-induced 
death [12, 13, 20]. In vivo, tumor growth was directly 
arrested by topical imiquimod treatment in an immune-
compromised mouse model of endometrial cancer [11]. In 
another study, imiquimod synergized with radiotherapy to 
enhance tumor regression via mechanisms dependent on 
the activation of autophagic pathways [21]. Together these 
results suggest that anti-tumor effects of imiquimod could 
play roles in tumor regression in cancer patients receiving 
imiquimod therapy. This is the case for many other anti-
cancer drugs, which deregulate oncogenic pathways and 
alter the expression of silenced and overexpressed genes, 
allowing for enhanced targeting by the immune system 
[22]. Further investigation of the molecular changes 
that occur in imiquimod-treated tumor cells is required 
to understand pathway regulation in response to this 
therapeutic molecule.
Devil facial tumor disease (DFTD) refers to two 
genetically distinct transmissible cancers (DFT1 and 
DFT2) threatening the survival of the world’s largest 
carnivorous marsupial, the Tasmanian devil (Sarcophilus 
harrisii). DFTD cells are transferred between devils in 
a contact dependent manner, where they successfully 
evade both allogeneic and anti-cancer immune defences 
to grow and survive in new hosts [23, 24]. Although the 
development of a prophylactic vaccine against DFTD 
is being investigated [25, 26], there are currently no 
prophylactic or therapeutic options for the protection of 
wild Tasmanian devils from the disease. Our previous 
studies have found that cell lines established from DFTD 
tumors are sensitive to cell death induced by imiquimod 
[27]. Furthermore, TLR7 signalling is functional in the 
immune system of the Tasmanian devil, suggesting that 
imiquimod could be an effective DFTD immunotherapy 
[28, 29]. Thorough investigation of imiquimod treated 
DFTD cells is required to identify direct imiquimod-
induced effects of potential detriment or benefit to tumour 
clearance in the Tasmanian devil. As these analyses are 
challenged by a lack of Tasmanian devil specific reagents, 
the effects of imiquimod in DFTD have been explored in 
this study at the whole mRNA and protein level using RNA 
sequencing (RNA-seq) and proteomic mass spectrometry 
(MS). The DFT1 cell line C5065 was selected as a model 
line for this analysis, as previous investigations have 
demonstrated that the response of these cells to imiquimod 
treatment is representative of other DFTD cell lines 
[27]. This study will improve the current understanding 
of DFTD tumorigenesis and survival, and could reveal 
new targets for DFTD therapy. As a naturally occurring 
tumor with established mechanisms of immune evasion 
and survival, DFTD also provides an ideal model for 
studying the mechanisms of imiquimod action for human 
application.
RESULTS AND DISCUSSION
Molecular changes to imiquimod-treated 
DFT1 cells
Imiquimod modulates tumor cell function by 
mechanisms that are thought to be independent of 
TLR7 signalling [17], but remain poorly understood 
in mammalian species including the Tasmanian devil. 
To understand the molecular pathways regulated by 
imiquimod in DFT1, we analysed the transcriptome 
and proteome of untreated and imiquimod-treated cells 
using RNA-seq and nanoHPLC-MS, respectively. As 
we previously determined that the percentage of early 
apoptotic DFT1 cells increases after 48 h of imiquimod 
treatment, this time point was chosen for promeomics 
analysis [27]. The transcriptome of imiquimod-treated cells 
was generated at an earlier time point of 24 h to minimise 
the extent of RNA degradation for sequencing analysis. 
After application of quality control filters described in 
the methods, 13,559 gene transcripts were detected by 
RNA-seq and 1057 proteins were detected by nanoHPLC-
MS in DFT1 cells (Figure 1A and 1B). The molecular 
landscape of imiquimod-treated and untreated DFTD 
cells was vastly different, with 2655 (19.58 %) mRNA 
transcripts significantly up regulated and 4188 (30.89 %) 
mRNA transcripts significantly down regulated when low 
stringency cut-offs were used (FDR < 0.05, FC > ±2.0). A 
more stringent FDR cut-off of 10-7 was chosen for down-
stream application, reducing the number of differentially 
expressed genes for functional analysis to 2786 (20.55 %). 
Statistical analysis of the label-free quantitative proteomics 
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data identified 136 (12.87 %) significantly up regulated 
proteins and 163 (15.42 %) significantly down regulated 
proteins after 48 h of imiquimod treatment (FDR < 0.05, 
FC > ±1.5). Comparison of the measured fold-changes of 
genes that were detected at both the mRNA and proteome 
level demonstrated a low but significant correlation of 
expression trends between the two datasets (R2 = 0.10, 
p < 0.0001) (Figure 1C). This low correlation may be a 
consequence of the different sampling time points for the 
mRNA and protein analysis, although different mechanisms 
for regulating mRNA and protein levels can also contribute 
to low overall correlation in large datasets [30, 31].
To identify functions associated with differentially 
expressed genes in imiquimod-treated DFT1 cells, 
gene ontology (GO) analysis was performed. The most 
significant GO_BP (biological process) terms associated 
with up regulated genes revealed deregulation of protein 
folding and activation of the unfolded protein response 
(UPR) in the endoplasmic reticulum (ER) in response 
to imiquimod treatment (Table 1A). Other functions 
Figure 1: Molecular changes to the transcriptome and proteome of imiquimod treated DFT1 cells. C5065 DFT1 cells were 
treated with imiquimod at 60 μg/ml for 24 or 48 h and analysed by RNA-seq and proteomic MS, respectively. (A) Differential mRNA levels 
and (B) differential protein levels between untreated and treated cells were measured and plotted against FDR. Genes with an expression 
fold-change of greater than ±2 (FDR < 0.05) and proteins with an expression fold-change of greater than ±1.5 (FDR < 0.05) are coloured 
blue. (C) Genes detected at both the mRNA and protein level were compared by log2(fold-change) and a linear regression was performed 
(dotted line). Grey lines represent an mRNA fold-change of ±2 and a protein fold-change of ±1.5.
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Table 1: Most significant biological process GO terms associated with genes regulated greater than 2-fold in 
imiquimod-treated DFT1 cells
GO ID GO term Term size Regulated p-value
A. Up regulated genes
GO:0035966 response to topologically incorrect protein 181 36 3.00 x 10-15
GO:0006986 response to unfolded protein 166 33 4.41 x 10-14
GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress 56 16 5.64 x 10
-10
GO:0006984 ER-nucleus signaling pathway 43 13 1.10 x 10-08
GO:0035967 cellular response to topologically incorrect protein 141 23 1.73 x 10-08
GO:0030968 endoplasmic reticulum unfolded protein response 125 21 4.25 x 10-08
GO:0034620 cellular response to unfolded protein 128 21 6.50 x 10-08
GO:1902235 regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway 29 10 1.37 x 10
-07
GO:0042594 response to starvation 150 22 2.46 x 10-07
GO:0000407 pre-autophagosomal structure 31 10 2.81 x 10-07
GO:0050821 protein stabilization 128 20 3.03 x 10-07
GO:0009267 cellular response to starvation 113 18 8.79 x 10-07
GO:1990440 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress 11 6 1.91 x 10
-06
GO:0036003 positive regulation of transcription from RNA polymerase II promoter in response to stress 23 8 2.35 x 10
-06
GO:0016126 sterol biosynthetic process 56 12 2.43 x 10-06
GO:0016241 regulation of macroautophagy 123 18 3.10 x 10-06
GO:0006695 cholesterol biosynthetic process 50 11 4.86 x 10-06
GO:1902653 secondary alcohol biosynthetic process 51 11 5.97 x 10-06
GO:0046685 response to arsenic-containing substance 26 8 6.70 x 10-06
GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress 62 12 7.48 x 10
-06
GO ID GO term Term size Regulated p-value
B. Down regulated genes
GO:0006261 DNA-dependent DNA replication 135 45 4.53 x 10-16
GO:0007062 sister chromatid cohesion 124 38 1.70 x 10-12
GO:0006270 DNA replication initiation 39 20 6.21 x 10-12
GO:0010001 glial cell differentiation 175 44 5.34 x 10-11
GO:0007422 peripheral nervous system development 69 24 1.19 x 10-09
GO:0061647 histone H3-K9 modification 38 16 3.01 x 10-08
GO:0000070 mitotic sister chromatid segregation 132 32 5.59 x 10-08
GO:0034329 cell junction assembly 192 40 1.19 x 10-07
GO:0007266 Rho protein signal transduction 151 34 1.50 x 10-07
(Continued )
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associated with ER stress such as apoptosis, autophagy 
and cholesterol biosynthesis were also positively 
regulated. Terms associated with genes down regulated 
by imiquimod indicated that DNA replication and cell 
cycle were arrested (Table 1B). Many down regulated 
terms were also associated with the Schwann cell origin 
of DFT1 cells, suggesting attenuation of normal DFT1 
function. Analysis of differentially expressed proteins 
using DAVID [32, 33] revealed up regulation of protein 
folding and down regulation of proteins associated 
with translation, confirming involvement of protein 
biosynthesis in the ER in response to imiquimod (Table 
2A-2B). Proteins associated with the mitochondria and 
spliceosomes were also positively regulated, and a role 
for disruption of redox homeostasis in the response to 
imiquimod was revealed. Together these findings suggest 
that functional changes that occur in imiquimod-treated 
DFT1 cells are related to the onset of stress responses and 
manifest at both the transcriptional and translational level. 
The principal functions regulated by imiquimod in DFT1 
cells are described in detail below.
ER stress responses
Investigations in tumor cell lines have determined 
that imiquimod is a strong inducer of oxidative and 
ER stress responses [16, 17, 19]. GO analysis of the 
DFT1 transcriptome and proteome confirmed that these 
responses were also activated in imiquimod-treated DFT1 
cells. To further understand these responses, we examined 
proteins up regulated by imiquimod for protein-protein 
interactions using the STRING database [34] (Figure 2). 
In support of previous findings, a network of ER proteins 
was up regulated in response to imiquimod treatment 
(green network). These proteins play key roles in ER 
stress-related functions such as protein re-folding and 
degradation, protein transport and calcium homeostasis. 
Binding immunoglobulin protein (BiP; HSPA5; FC = 2.7, 
p = 6.48x10-4), a master regulator of ER stress responses 
in other species [35], was included in this protein network.
BiP regulates the UPR, an adaptive response of three 
key signalling networks, to restore ER homeostasis and 
promote cell survival during cellular stress (the IRE1-
XBP1, ATF6 and PERK-EIF2α-ATF4 pathways). These 
pathways reduce protein damage and overload within 
the ER through increased capacity for protein folding 
(IRE1-XBP1 and ATF6 pathways), removal of terminally 
misfolded proteins via ER-associated degradation (ERAD) 
(IRE1-XBP1 and ATF6 pathways) and attenuation of 
protein translation to mitigate ER protein overload 
(PERK-EIF2α-ATF4 pathway) [36–38]. To determine 
whether UPR pathways were activated by imiquimod, we 
analysed differentially expressed genes that were detected 
by RNA-seq analysis in more detail using Ingenuity 
Pathway Analysis (IPA). Analysis of predicted canonical 
pathways revealed that ‘Unfolded protein response’ (p 
= 4.x10-09) and ‘Endoplasmic reticulum stress pathway’ 
(p = 1x10-06) were two of the most over-represented 
and significantly modulated pathways associated with 
imiquimod treatment in DFT1 cells (Supplementary Table 
3). Further examination of the pathway ‘Unfolded protein 
response’ demonstrated that components of all three UPR 
pathways were positively regulated at the gene level, 
suggesting that imiquimod induces significant ER stress 
in DFT1 cells (Figure 3). This finding was confirmed 
through quantitative RT-PCR gene expression analysis of 
the key UPR markers HSPA5 (CHOP), XBP1 and DDIT3 
(CHOP) across four imiquimod treated DFT1 cell lines 
(C5065, 1426, 4906 and half-pea; Supplementary Figure 
1). Significant increases in the expression of UPR markers 
GO ID GO term Term size Regulated p-value
B. Down regulated genes
GO:0031570 DNA integrity checkpoint 159 35 1.79 x 10-07
GO:0032392 DNA geometric change 81 23 1.94 x 10-07
GO:0032508 DNA duplex unwinding 76 22 2.46 x 10-07
GO:0007160 cell-matrix adhesion 193 39 3.94 x 10-07
GO:0042552 myelination 103 26 4.14 x 10-07
GO:0007272 ensheathment of neurons 106 26 7.54 x 10-07
GO:0008366 axon ensheathment 106 26 7.54 x 10-07
GO:0007088 regulation of mitotic nuclear division 133 30 7.64 x 10-07
GO:0006271 DNA strand elongation involved in DNA replication 23 11 9.49 x 10-07
GO:1901988 negative regulation of cell cycle phase transition 156 33 1.03 x 10-06
GO:0090329 regulation of DNA-dependent DNA replication 42 15 1.04 x 10-06
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were measured across 72 h of imiquimod treatment in all 
four lines, confirming that UPR pathways are stimulated 
by imiquimod in DFT1 cells.
The UPR plays a key role in determination of cell 
fate during ER stress, and can activate expression of pro-
apoptotic CHOP (DDIT3) and JNK1 (MAPK8) when cell 
stress and damage cannot be resolved. Specifically, the 
PERK-ATF4 axis, which regulates pro-apoptotic CHOP 
(DDIT3; FC = 42.6, FDR = 1.91x10-10) and pro-survival 
GADD34 (PPP1R15A; FC = 34.0, FDR = 4.13x10-11), 
was positively regulated at the mRNA level in our study 
and provides the first evidence for ER-stress mediated cell 
death in imiquimod treated DFT1 cells. Our findings are 
consistent with activation of both CHOP and GADD34 
gene expression, suggesting that ER stress pathways play 
roles in determining cell fate during imiquimod treatment.
Mitochondrial stress responses
The UPR is also known to modulate protein 
expression within the mitochondria, where protein damage 
can have deleterious effects on metabolic processes [39]. 
Consistent with a role of the mitochondria in imiquimod-
induced cell stress, STRING analysis of proteins up-
regulated by imiquimod revealed a network containing 
mitochondrial VDAC channels (VDAC1, FC = 2.5, p = 
Table 2: Representative enriched ontological terms associated with proteins regulated greater than 1.5-fold in 
imiquimod-treated DFT1 cells
Category Term No. proteins Enrichment Score p-Value FDR
(A) Up-regulated proteins
GOTERM_MF_DIRECT poly(A) RNA binding 60 18.53 3.69E-31 5.08E-28
GOTERM_BP_DIRECT mRNA spicing, via spliceosome 29 16.71 7.28E-25 1.13E-21
GOTERM_CC_DIRECT nucleoplasm 58 12.71 8.30E-12 1.09E-08
GOTERM_CC_DIRECT spliceosomal complex 10 9.54 7.99E-08 1.05E-04
GOTERM_BP_DIRECT protein folding 19 9.18 4.72E-06 2.95E-11
GOTERM_CC_DIRECT intracellular ribonucleoprotein complex 15 6.26 6.37E-12 8.36E-09
UP_KEYWORDS mitochondrion 29 6.18 8.83E-09 1.14E-05
GOTERM_CC_DIRECT endoplasmic reticulum lumen 17 4.74 4.90E-12 6.43E-09
GOTERM_BP_DIRECT cell redox homeostasis 8 4.35 4.49E-06 6.98E-03
GOTERM_BP_DIRECT negative regulation of mRNA splicing, via spliceosome 6 3.71 8.16E-07 1.27E-03
(B) Down-regulated proteins
GOTERM_BP_DIRECT translational initiation 51 45.75 1.62E-67 2.58E-64
GOTERM_CC_DIRECT cell-cell adherens junction 30 18.55 4.01E-21 5.31E-18
GOTERM_BP_DIRECT tRNA aminoacylation for protein translation 7 3.91 2.15E-06 3.43E-03
INTERPRO actin/actin-like conserved site 5 3.81 3.13E-05 4.51E-02
INTERPRO armadillo-type fold 16 3.57 5.43E-07 7.83E-04
GOTERM_BP_DIRECT regulation of translational initiation 7 3.34 1.13E-06 1.79E-03
GOTERM_MF_DIRECT translation initiation factor activity 7 3.23 2.83E-05 3.81E-02
UP_KEYWORDS Neurodegeneration 11 3.08 1.32E-04 1.68E-01
GOTERM_BP_DIRECT vesicle mediated transport 8 2.27 6.85E-04 1.09E+0
UP_KEYWORDS ATP binding 24 2.63 7.46E-04 9.47E-01
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Figure 2: Interactions of proteins up regulated by imiquimod in DFT1 cells. C5065 DFT1 cells were treated with imiquimod 
at 60 μg/ml for 48 h. The proteome of treated and untreated cells was analysed by proteomic MS. Proteins significantly up regulated greater 
than 1.5-fold (FDR < 0.05) were analysed for protein-protein interactions using the STRING database. Only interactions predicted with 
high confidence were included in the analyses, and proteins with no predicted interactions were removed. Functional groups were assigned 
based on scientific literature.
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1.56x10-3; VDAC2, FC = 2.1, p = 1.76x10-2; VDAC3, 
FC = 1.8, p = 5.91x10-2) and numerous stress inducible 
mitochondrial chaperone proteins (HSP10 (HSPE1; FC 
= 1.7, p = 3.74x10-3), HSP60 (HSPD1; FC = 2.0, p = 
3.74x10-5), HSP70 (HSPA9; FC = 1.8, p = 2.45x10-5) and 
HSP105 (HSPH1; FC = 2.1, p = 2.19x10-4)) (red network) 
(Figure 2). Mitochondrial chaperones can be activated by 
disruptions to oxidative phosphorylation that produce an 
excess of unassembled respiratory chain components in 
the mitochondria [40]. Key protein subunits of respiratory 
chain complexes III (UQCRFS1; FC = 8.8, p = 1.61x10-2), 
IV (COX4I1; FC = 1.7, p = 8.78x10-3) and V (ATP5A1, 
FC = 1.5, p = 9.40x10-4; ATP5B, FC = 2.5, p = 1.62x10-3) 
were up regulated in DFT1 cells (yellow network), 
demonstrating involvement of oxidative phosphorylation 
in the response to imiquimod treatment.
Disruptions to oxidative phosphorylation could 
explain a shift in redox balance in imiquimod treated 
DFT1 cells. Proteins associated with cellular responses 
to oxidative stress such as catalase (CAT; FC = 2.2, p 
= 7.76x10-5) and thioredoxin reductase 1 (TXNRD1; 
FC = 2.1, p = 4.02x10-4) were up regulated, suggesting 
that elevated levels of reactive oxygen species (ROS) 
are present after imiquimod treatment (Figure 2). ROS 
could shuttle between the ER and mitochondria to alter 
protein homeostasis and further exacerbate the ER stress 
Figure 3: Regulation of the unfolded protein response in DFT1 cells by imiquimod. C5065 DFT1 cells were treated with 
imiquimod at 60 μg/ml for 24 h. The transcriptome of treated and untreated cells was analysed by RNA-seq and IPA was used to predict 
canonical pathways regulated by imiquimod treatment. The significantly regulated canonical pathway ‘Unfolded protein response’ is 
shown. Up-regulated genes are coloured red and down-regulated genes are coloured blue.
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response [41]. Calcium released from the ER during stress 
is also taken up by mitochondrial ion channels such as 
VDACs, and can further stimulate ROS production [42]. 
Such a mechanism of action is supported by previous 
observations of heightened levels of intracellular ROS and 
depletion of ER calcium in imiquimod-treated tumor cells 
[17, 43]. The involvement of ROS in the stress response 
to imiquimod likely explains the susceptibility of tumor 
cells to imiquimod-induced apoptosis. ROS accumulates 
at a faster rate in highly metabolic tumor cells, leading to 
detrimental conditions that promote apoptotic pathways 
[44]. Pro-survival mechanisms such as the UPR are also 
constitutively active in tumors to cope with high metabolic 
demands, and additional production of ROS is more 
likely to overwhelm these mechanisms to promote a pro-
apoptotic state [45].
Tumorigenesis
The UPR modulates translation to prevent protein 
overload within the ER and to promote pro-survival 
responses during cellular stress [38, 46]. This attenuation 
of translation is controlled by PERK (EIF2AK3), which 
phosphorylates the translational regulator EIF2A leading 
to preferential biosynthesis of stress-related proteins and 
suppression of overall protein translation [38, 46]. To 
determine how these translational changes alter the DFT1 
landscape, we further analysed canonical pathways that 
were predicted by IPA to be regulated by imiquimod 
treatment. Investigation of these pathways revealed an 
overall suppression of tumorigenesis in imiquimod-treated 
DFT1 cells, with down regulation of numerous pathways 
involved in tumorigenic processes such as proliferation, 
resistance to apoptosis, angiogenesis, immune evasion, 
migration and invasion (Supplementary Table 3) [47–
50]. Examples of these included ‘Integrin Signalling’ (p 
= 3x10-10), ‘STAT3 Pathway’ (p = 1x10-08) and ‘Protein 
Kinase A Signalling’ (p = 2x10-08). The canonical pathway 
most significantly associated with the RNA-seq dataset 
was ‘Molecular Mechanisms of Cancer’ (p = 6x10-13) 
(Figure 4). Analysis of this pathway in detail revealed 
additional networks by which imiquimod influenced 
tumor growth, with deregulation of cyclin signalling and 
strong up-regulation of p21CIP1 (CDKN1A; FC = 12.1, 
FDR = 2.69x10-10), an inducer of replicative senescence, 
at the mRNA level. Genes encoding pathways that 
promote cell cycle, DNA repair and proliferation were 
also negatively regulated, including Ras, p53, BRCA1, 
integrin, phospholipase C and Hedgehog signalling 
pathways. Other pathways, such as NFκB, p38 MAPK and 
NOTCH1 signalling pathways were positively regulated 
at the mRNA level, and may play roles in the response to 
imiquimod treatment.
With such potent effects on tumorigenesis, 
imiquimod may increase the ability of immune cells to 
mount anti-tumor cytotoxic responses in vivo. In support 
of this, the death receptor FAS was present at only low 
mRNA levels in the transcriptome of untreated DFT1 
cells and was up regulated by imiquimod treatment (FC 
= 23.7, FDR = 1.12x10-9; Figure 4). FAS expression is 
frequently suppressed in tumor cells to evade immune-
mediated cytotoxicity and is functionally up regulated 
in an immune-independent manner in response to other 
anti-cancer drugs such as cisplatin and doxorubicin 
[51]. Up regulation of FAS expression in imiquimod-
treated DFT1 cells could increase their susceptibility 
to immune-mediated cytotoxicity. In addition, the anti-
phagocytic gene CD200 (FC = 0.1, FDR = 1.08x10-9), 
the angiogenic gene VEGFA (FC = 0.5, FDR = 8.24x10-7) 
and the checkpoint inhibitor CD276 (FC = 0.2, FDR = 
2.20x10-8) were down regulated at the mRNA level in 
DFT1 cells by imiquimod treatment (Supplementary Table 
1). As these molecules suppress immune responses, their 
down regulation provides further evidence for increased 
immunogenicity of imiquimod-treated DFT1 cells. Other 
regulatory molecules such as PDL1 (CD274) exhibited 
low or no expression at baseline in DFT1 cells and were 
not up regulated at the mRNA level by imiquimod.
Cell cycle arrest
Previous studies in animal models have 
demonstrated immune-independent suppression of tumor 
growth in response to imiquimod treatment in vivo [11]. 
This suppression of tumor growth is likely the result of 
UPR-induced cell cycle arrest, which allows time for cell 
damage to be repaired prior to cell division. In support 
of this, genes found to be positively regulated in DFT1 
cells at the mRNA level by imiquimod included the 
cyclin/cyclin dependent kinase (CDK) inhibitor p21CIP1 
(CDKN1A; FC = 12.1, FDR = 2.69x10-10), an inducer 
of replicative senescence at the G1/S phase (Figure 4). 
Consistent with these findings, network analysis of the 
DFT1 transcriptome using IPA revealed that the canonical 
pathway ‘Cell cycle control of chromosomal replication’ 
was the second most significant pathway associated with 
imiquimod treatment (p = 3x10-11; Figure 5). Analysis 
of this pathway revealed strong suppression of mRNA 
encoding necessary components of chromosomal 
replication machinery, including MCM (including MCM6; 
FC = 0.2, FDR = 4.07x10-11), RPA (RPA1; FC = 0.2, FDR 
= 5.92x10-10), CDT1 (CDT1; FC = 0.2, FDR = 1.53x10-9) 
and DNA polymerase (including POLA1; FC = 0.2, FDR 
= 3.44x10-10). CDKs, which are required for cell cycle 
progression, were also highly suppressed at the mRNA 
level. CHK2 (CHEK2), an upstream negative regulator of 
CDK activity at the G1/S phase, was up regulated (FC = 
2.9, FDR = 3.43x10-8). In comparison, genes encoding the 
G2/M cyclin/CDK inhibitor CHK1 (CHEK1) were down 
regulated at the mRNA level after 24 h of imiquimod 
treatment (FC = 0.3, FDR = 3.72x10-9). Together these 
results indicate that imiquimod suppresses DFT1 cell 
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cycle at the G1/S phase after 24 h of treatment. This 
finding supports previous analysis of imiquimod action in 
DFT1 cell lines, which demonstrated significant inhibition 
of cell proliferation after treatment [27].
G1/S cell cycle arrest during ER stress is controlled 
through PERK-dependent preferential translation of p53 
(TP53) [52]. Unexpectedly, p53 was down regulated in 
imiquimod-treated DFT1 cells at the mRNA level (FC = 
0.3, FDR = 3.77x10-9; Supplementary Table 1), opposing 
its role in imiquimod-induced G1/S arrest. In studies by 
Huang and colleagues, expression of p53 was up regulated 
by imiquimod in tumor cells at 24 h and was required for 
more rapid onset of apoptosis when compared to p53 
knockdown cells [18]. Although p53 was down regulated 
in DFT1 cells by imiquimod treatment, targets of p53 
such as MDM2, PTEN and FAS were up regulated in 
the transcriptome, suggesting that p53 function was not 
lost. As such, the apparent down regulation of p53 in 
imiquimod-treated DFT1 cells could be time-dependent, 
and may represent a negative feedback mechanism to 
promote cell survival during the early stages of treatment. 
Alternatively, p53-independent activation of p21CIP1 
(CDKN1A), via mechanisms involving CHK2 (CHEK2), 
has been reported in other models and could play a role in 
G1/S cell cycle arrest in DFT1 cells [53].
Figure 4: Regulation of ‘Molecular mechanisms of cancer’ canonical pathway in DFT1 cells by imiquimod. C5065 DFT1 
cells were treated with imiquimod at 60 μg/ml for 24 h. The transcriptome of treated and untreated cells was analysed by RNA-seq and IPA 
was used to predict canonical pathways regulated by imiquimod treatment. The canonical pathway most significantly associated with genes 
regulated by imiquimod treatment is shown. Up-regulated genes are coloured red and down-regulated genes are coloured blue.
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Figure 5: Regulation of ‘Cell cycle control of chromosomal replication’ canonical pathway in DFT1 cells by imiquimod. 
C5065 DFT1 cells were treated with imiquimod at 60 μg/ml for 24 h. The transcriptome of treated and untreated cells was analysed by 
RNA-seq and IPA was used to predict canonical pathways regulated by imiquimod treatment. The highly regulated pathway ‘Cell cycle 
control of chromosomal replication’ is shown. Up-regulated genes are coloured red and down-regulated genes are coloured blue.
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Autophagy
It is well established that tumor cells treated in vitro 
with imiquimod undergo cell death [14, 16]. In addition 
to apoptosis, autophagy has been implicated in cell death 
pathways [12, 16, 19]. In support of a role for autophagy 
in the response of DFT1 cells to imiquimod treatment, 
our proteomic analysis revealed up regulation of the 
lysosomal proteins CTSB (FC = 1.8, p = 1.05x10-2) and 
LAMP1 (FC = 1.6, p = 1.50x10-3) (Figure 2). To further 
investigate the involvement of autophagy in these treated 
cells, mRNA expression of genes with known roles in 
the regulation and execution of autophagy was analysed 
by hierarchical clustering and represented using a heat 
map. Many autophagic genes, including class III PI3K 
(PIK3C3), an activator of autophagy, were expressed in 
both untreated and imiquimod-treated DFT1 cells at the 
mRNA level (Figure 6A). Furthermore, mRNA encoding 
P150 (PIK3R4), which is required for stabilisation and 
correct function of the class III PI3K complex, was 
positively regulated in response to imiquimod treatment 
(FC = 2.3, FDR = 5.67x10-9). Other critical genes required 
for formation of the autophagosome (BECN1, ATG9A and 
ATG2A), autophagosome and lysosome fusion (RAB7A) 
and lysosomal protein degradation (LAMP1, LAMP2 and 
CTSA) were either highly expressed in both untreated and 
treated cells, or were up regulated in response to imiquimod 
treatment, suggesting that autophagic pathways were active.
During ER stress, autophagic gene expression is 
stimulated by PERK-ATF4-mediated transcriptional 
activity [54]. Autophagy is then activated via the IRE1-
JNK axis, which mediates phosphorylation of anti-
apoptotic BCL2 and induces its dissociation from the 
autophagy inducer beclin-1 [55, 56]. Although autophagic 
pathways have the potential to induce cell death, they 
are initially activated as a protective anti-apoptotic 
Figure 6: Relative expression of genes associated with autophagy and apoptosis in DFT1 cells after imiquimod 
treatment. C5065 DFT1 cells were treated with imiquimod at 60 μg/ml for 24 h. The transcriptome of treated and untreated cells was 
analysed by RNA-seq. Relative expression of genes associated with (A) autophagic pathways and (B) apoptotic pathways in untreated (UT) 
and imiquimod-treated (IM) cells was visualized on heat maps generated by Euclidean clustering. High gene expression is represented in 
red and low gene expression is represented in blue.
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mechanism by which damaged proteins and organelles are 
degraded and recycled to minimize cellular stress [55]. In 
support of this, genes encoding key inhibitors of apoptosis 
including MCL1, XIAP (ENSSHAG00000016328) and 
BIRC2 (ENSSHAG00000011782) were highly expressed 
at the mRNA level in tandem with autophagic genes after 
24 h of imiquimod treatment (Figure 6B). These results 
suggest that autophagic pathways may play a role in 
promoting and prolonging DFT1 survival after imiquimod 
treatment.
Apoptosis
Unresolved cellular stress and prolonged activation 
of the UPR leads to stimulation of apoptotic pathways. 
This can occur via direct UPR stimulation of CHOP 
(PERK-EIF2a-ATF4 pathway) and JNK1 (IRE1-ASK1 
pathway), which regulate pro and anti-apoptotic proteins 
such as BIM, BCL2 and XIAP to stimulate apoptosis 
[57–59]. An additional mechanism of stress-mediated 
apoptosis is activated through the calcium-dependent 
pro-apoptotic protein calpain after ER calcium depletion 
[60, 61]. Previous analyses have shown that DFT1 cell 
lines undergo apoptosis after sustained treatment with 
imiquimod [27]. Direct measurement of pro- and anti-
apoptotic factors in this previous study revealed down 
regulation of anti-apoptotic genes and up regulation of the 
pro-apoptotic gene BIM (BCL2L11) at the mRNA level in 
response to imiquimod treatment. To further understand 
these apoptotic pathways, genes associated with apoptosis 
were also analysed by hierarchical clustering and 
visualized using a heat map (Figure 6B). As demonstrated 
in Figure 3, CHOP (DDIT3; FC = 42.6, FDR = 1.91x10-10) 
was highly up regulated at the gene level in imiquimod-
treated DFT1 cells, while JNK1 exhibited high constitutive 
expression that was unchanged after treatment. Isoforms 
of calpain were differentially regulated, with strong 
suppression of the μ-isoform CAPN1 (FC = 0.04, FDR = 
2.62x10-9) and up regulation of the m-isoform CAPN2 (FC 
= 2.5, FDR = 4.74x10-9) at the mRNA level. M-calpain 
can directly activate apoptosis via cleavage of caspase 12, 
and also interacts with the IRE1-ASK1 pathway during 
ER stress to promote JNK1-mediated apoptosis [61]. In a 
previous study, individual inhibition of JNK1, CHOP and 
calpain pathways slowed but did not prevent imiquimod-
induced cell death [16]. This finding suggests that 
cooperation of these pathways is required for activation of 
apoptosis after imiquimod treatment.
Mitochondrial pro-apoptotic genes such as BCL2L11 
(FC = 7.7, FDR = 9.56x10-10), DIABLO (FC = 3.1, FDR = 
2.59x10-8) and ENDOG (FC = 1.8, FDR = 8.85x10-4) were 
also positively regulated at the gene level by imiquimod 
in DFT1 cells and likely play roles in the activation of 
apoptotic pathways (Figure 6B). Specifically, ENDOG 
encodes a key inducer of caspase-independent apoptosis 
and DNA fragmentation during sustained endogenous 
oxidative stress, and could be stimulated by imiquimod-
induced ROS [62, 63]. Activation of apoptotic pathways 
also requires the spliceosome, which alternatively splices 
numerous apoptotic regulators to modulate their pro- 
and anti-apoptotic functions [64]. This regulation is 
evident after imiquimod treatment, with a large network 
of proteins involved in mRNA splicing and processing 
identified by STRING interaction analysis (blue 
network) (Figure 2). These include all three members 
of the apoptosis and splicing associated protein (ASAP) 
complex (ACIN1, FC = 2.5, p = 4.20x10-4; SAP18, FC 
= 3.0, p = 3.63x10-4; RNPS1, FC = 2.3, p = 9.58x10-4), 
which is involved in the alternative splicing of regulators 
of apoptosis including caspases and the members of the 
BCL2 protein family [64].
Mechanism of action
Although pathways by which imiquimod modulates 
cell death have been identified, little is understood as to 
how these mechanisms are activated. As a potent agonist 
of TLR7, it is tempting to hypothesize that imiquimod 
induces ER stress and apoptosis in tumor cells via TLR7 
signalling. However, studies have shown that tumor cell 
lines lacking TLR7 are also sensitive to imiquimod-
induced autophagy and apoptosis [17, 19, 43]. We 
previously reported that DFTD cells also do not express 
TLR7 at any stage of imiquimod treatment, suggesting 
that imiquimod acts via a TLR7-independent mechanism 
in DFT1 cells [27]. Myeloid cells treated with imiquimod 
undergo a ROS burst that is activated via direct inhibition 
of NAD(P)H quinone dehydrogenase 2 (NQO2) and 
complex I of the respiratory chain [10]. Similar direct 
inhibition of complex I in highly metabolic tumor 
cells would shift oxidative homeostasis, leading to the 
activation of mitochondrial and ER stress responses. This 
is the case for other known inhibitors of complex I, which 
demonstrate anti-cancer effects involving substantial ROS 
production and ER stress [65, 66]. Decreased oxidative 
respiration and ATP depletion have been measured in 
imiquimod-treated tumor cells, providing evidence for 
respiratory chain inhibition [19, 43]. In contrast, key 
subunits of complexes III, IV and V were up regulated at 
the mRNA level in imiquimod-treated DFT1 cells (Figure 
2). These complexes may have been up regulated as a 
compensatory mechanism for ATP depletion, and could 
add to oxidative stress at the mitochondria in a vicious 
stress cycle. Studies targeting specific key elements 
are required to further investigate the mechanism of 
imiquimod action in tumor cells.
Implications for imiquimod therapy
The potent anti-tumor effects of imiquimod in DFT1 
cells have highlighted the potential of stress responses as 
targets for deregulation of DFTD tumor cell survival. 
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Figure 7: Proposed mechanism of imiquimod action in DFTD cells. 1. Induction of cell stress (red arrows): Imiquimod enters 
the cell and disrupts oxidative phosphorylation at the mitochondria via a TLR7-independent mechanism. ROS is produced and shuttles 
between the ER and mitochondria to disrupt cellular homeostasis and activate the UPR. Ca2+ is depleted from the ER upon activation of ER 
stress, and is taken up by the mitochondria where it further disrupts oxidative phosphorylation in a stress-induced cycle. 2. Attenuation of 
protein translation and cell cycle arrest (orange arrows): PERK is activated by the UPR and phosphorylates EIF2a, resulting in attenuation 
of regular protein translation and suppression of oncogenic pathways. EIF2a induces cell cycle arrest through preferential translation of 
cyclin inhibitors such as p21CIP1. 3. Activation of autophagy (green arrows): PERK stimulates the expression of genes required for stress 
responses via ATF4, including autophagic genes. IRE1 is activated via the UPR and stimulates JNK via ASK1. Increased cytoplasmic 
Ca2+ activates m-calpain, which further stimulates JNK activity via ASK1. JNK phosphorylates BCL2, resulting in its dissociation from 
beclin-1, and allowing beclin-1 to induce autophagy. 4. Inhibition of apoptosis (blue arrows): Activation of autophagy inhibits apoptosis, 
in part through the release of BCL2. BCL2 inhibits the XIAP inhibitor DIABLO and cytochrome C release. DFTD cells survive in this 
state for up to 72 h. 5. Activation of apoptosis (purple arrows): Prolonged cell stress induces the expression of pro-apoptotic CHOP via 
the PERK-ATF4 axis. JNK activates pro-apoptotic members of the BCL2 family such as BIM. CHOP, JNK and BIM cooperated to inhibit 
anti-apoptotic molecules including BCL2. Inhibition of BCL2 activates DIABLO, which inhibits anti-apoptotic XIAP. Cytochrome C is 
released from the mitochondria, and stimulates the caspase cascade. M-calpain supports the activation of this pathway through cleavage of 
caspase 12. ENDOG is also released from the mitochondria in response to prolonged oxidative stress and promotes DNA degradation in a 
caspase-independent manner. DFTD cells undergo apoptosis.
Indeed, our results showed that pro-survival pathways 
including autophagy, the UPR and antioxidant signalling 
were overwhelmed by imiquimod-induced cell stress in 
DFT1 cells, demonstrating the potential of stress-inducing 
drugs as therapeutic agents in DFTD. Imiquimod has also 
been found to be an effective immune adjuvant in the 
Tasmanian devil [28, 29], supporting its use as a DFTD 
immunotherapy. Although imiquimod would be difficult 
to distribute among a wild devil population, the drug could 
be available for opportunistic treatment of captured devils 
affected by the disease. As DFTD tumors are allografts 
[24], it is possible that only a short period of imiquimod 
treatment would be required to break immune tolerance 
and induce allogeneic immunity. Captive trials are 
required to determine whether imiquimod is an effective 
immunotherapy in the Tasmanian devil.
Studies of imiquimod action in DFTD also provide 
valuable insights into the response of human tumor 
cells to direct imiquimod treatment. While previous 
studies have elucidated a role for imiquimod in the 
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activation of stress responses in human cancer cell 
lines [16, 17], our analyses have used DFTD as a tumor 
model to highlight the key molecules and pathways 
regulated at a global scale. In human cancer therapy, 
combinatorial immunotherapies have demonstrated 
promise for their ability to target multiple pathways 
and overcome immune resistance [67]. Through an 
improved understanding of pathways regulated by 
imiquimod, the approach used in our analysis will allow 
for mechanistic identification of potential therapeutic 
targets and drug combinations involving imiquimod 
treatment. Our analysis also provides evidence that 
imiquimod exerts suppressive effects against pathways 
involved in the normal functioning of tumor cells, 
including those involved in invasion, cell migration 
and immune evasion. These suppressive effects could 
improve the ability of the immune system to target tumor 
cells, perhaps aiding tumor rejection in vivo. This study 
provides a basis for further exploration of imiquimod as 
a therapy in cancer.
MATERIALS AND METHODS
Cell lines and imiquimod treatment
The DFT1 cell lines C5065, 1426, 4906 and half-
pea were provided by A.-M. Pearse and K. Swift of the 
Tasmanian Department of Primary Industries, Parks, Water 
and Environment (DPIPWE). A total of 1 x 106 cells were 
plated per well of a 12-well cell culture plate (Corning, 
New York, USA) in 1 ml of RPMI culture medium 
(Thermo Fisher Scientific, Waltham, USA)/10% foetal calf 
serum (FCS). Cells were treated with imiquimod (Sigma-
Aldrich, St Louis, USA) prepared as previously described 
[27], at 60 μg/ml in a 35 °C, 5% CO2 humidified incubator. 
As it was previously determined that DFT1 cells undergo 
imiquimod-mediated cell death after 24-96 h incubation 
with the drug [27], cells were treated for 24 h for RNA-seq 
to ensure mRNA integrity. A longer treatment of 48 h was 
used for proteomics analysis in order to understand the 
changes occurring as the cells enter apoptotic pathways. 
For confirmation of findings by quantitative PCR, cells 
were treated for 0, 8, 16, 24, 48 or 72 h, and PCR was 
performed according to previously described methods 
[27]. Untreated controls were included in all analyses.
Next generation mRNA sequencing
RNA was extracted from untreated and imiquimod-
treated C5065 DFT1 samples using the RNeasy® Mini Kit 
(QIAGEN Bioinformatics, Hilden, Germany), according 
to the manufacturer’s instructions. RNA integrity was 
assessed using a Eukaryotic RNA 6000 Nano Kit and 
2100 Bioanalyzer (Agilent, Santa Clara, USA). 100 base-
pair single-read mRNA sequencing was performed on 
the Illumina Hiseq-2000 platform (Illumina, San Diego, 
USA). The RNA-seq data have been deposited to the 
NCBI Sequence Read Archive (BioSample accessions 
SAMN07998608, SAMN07998609, SAMN07998610, 
SAMN07998611) with links to BioProject accession 
number PRJNA416378 in the NCBI BioProject 
database (https://www.ncbi.nlm.nih.gov/bioproject/). 
Sequence quality was assessed using fastqc (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc). 
Sequencing reads were aligned to the Tasmanian devil 
reference genome (7.0.82) using subread [68], and 
counts were summarized into genes using featureCounts 
[69]. Differential expression analysis of gene counts 
was performed using R version 3.3.2. For this analysis, 
technical replicates were combined and genes with less 
than 20 aligned reads across all samples were removed. 
Expression levels were normalized by upper quartile 
normalisation using EDAseq [70, 71]. Differential 
expression was calculated using limma/voom [72] 
(Supplementary Table 1). Volcano plots of differential 
gene expression data were created using the R plot 
function, and heat maps were produced using heatmap.2/
gplots (https://CRAN.R-project.org/package=gplots) 
using hierarchical clustering by Euclidean distance. Gene 
ontology (GO) analysis of genes up and down regulated 
greater than 2-fold was performed using limma/goana 
[73, 74] (Supplementary Table 2A-2B). A stringent FDR 
cut-off of 10-7 was applied to this analysis to include 
only the most significantly altered genes. To remove 
general and repetitive GO terms, those with a gene 
size of greater than 200 were filtered from the analysis. 
Differential gene expression data was further analysed 
using Ingenuity Pathway Analysis (IPA; QIAGEN) 
[75]. Canonical pathways associated with differentially 
expressed genes were generated using the FDR cut-off of 
10-7 (Supplementary Table 3).
Nano-liquid chromatography and LTQ-Orbitrap 
tandem mass spectrometry
Triplicate cultures of untreated and imiquimod-
treated C5065 DFT1 cells were lysed in 700 μl of protein 
extraction buffer (7M urea/2M thiourea in 40 mM Tris 
with protease inhibitor, pH 8.0) for 2 h at 4 °C. Proteins 
were precipitated from the lysate with 9 x the volume 
of 100 % ethanol overnight at -20 °C. Proteins were 
reconstitutes in protein extraction buffer and concentration 
was determined using the EZQ® Protein Quantification 
Kit (Thermo Fisher Scientific, Waltham, USA), according 
to the manufacturer’s instructions. Precipitated proteins 
were sequentially reduced, alkylated and digested with 
proteomics-grade trypsin from porcine pancreas (Sigma-
Aldrich, St Louis, USA) as previously described [76]. 
Tryptic peptides equivalent to ~ 1 μg of digested protein 
were separated using an Ultimate 3000 nano RSLC system 
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(Thermo Fisher Scientific, Waltham, USA). Peptides 
were first concentrated on a 20 mm x 75 μm PepMap 
100 trapping column (3 μm C18) at a flow rate of 5 μl/
min, using 98 % water, 2 % acetonitrile and 0.05% TFA. 
Peptides were then separated on a 250 mm x 75 μm 
PepMap 100 RSLC column (2μm C18) at a flow rate of 
300 nL/min. A 180 minute gradient from 98% mobile 
phase A (0.1% formic acid in water) to 50% mobile phase 
B (0.08% formic acid in 80% acetonitrile and 20 % water) 
comprised the following steps: 2-10% B over 10 min, 10-
40% B over 120 min, 40-50% B over 10 min, holding 
at 95% B for 10 min then re-equilibration in 2% B for 
15 min. The nanoHPLC system was coupled to an LTQ-
Orbitrap mass spectrometer equipped with nanopray Flex 
ion source (Thermo Fisher Scientific, Waltham, USA) and 
controlled using Xcalibur 2.1 software. MS scans were 
acquired from 460-2000 m/z at a resolution of 30,000 and 
MS/MS spectra were acquired in data-dependent mode 
using a Top8 method and 30-second dynamic exclusion 
of fragmented peptides, as described [77]. The mass 
spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE [78] partner 
repository with the dataset identifier PXD007135.
Protein identification and analysis
Data files were imported into MaxQuant version 
1.5.1.2 (http://maxquant.org/) and MS/MS spectra were 
searched using the Andromeda search engine against the 
complete Sarcophilus harrisii UniProt reference proteome 
(ID 0000007648; updated on 11/02/2016) comprising 
22,388 protein entries. Default settings for protein 
identification by LTQ-Orbitrap MS/MS and label-free 
quantitation (LFQ) included a maximum of two missed 
cleavages, mass error tolerances of 20 ppm then 4.5 ppm 
for initial and main peptide searches, respectively, 0.5 Da 
tolerance for fragment ions, variable methionine oxidation 
and fixed carbamidomethylation. A default false discovery 
rate (FDR) of 0.01 was used for peptide-spectrum matches 
and protein identification. The MaxQuant algorithm 
MaxLFQ was used for peptide intensity determination and 
normalization [79], using pair-wise comparison of unique 
and razor peptide intensities and a minimum ratio count of 
2. The proteinGroups output file generated by MaxQuant 
analysis was processed as follows: The normalized label-
free quantification (LFQ) intensity values, MS/MS counts 
and the numbers of razor and unique peptides for each 
of the identified proteins were imported into Perseus 
software version 1.5.031 (http://perseus-framework.org/). 
Protein groups identified either as potential contaminants 
(prefixed with CON_), identified by modified site only, 
by reverse database matching or on the basis of a single 
matching peptide were removed. LFQ intensity values 
were then log2–transformed and then a filter applied to 
include only proteins detected in a minimum of the three 
untreated or imiquimod treated replicates. Missing values 
were replaced with random intensity values for low-
abundance proteins based on a normal distribution of 
protein abundances using default MaxQuant parameters. 
To determine proteins that were significantly altered in 
abundance between treatments a two-sided t-test with a 
permutation-based FDR of 0.05 was applied, using 250 
randomizations and a minimum fold-change cut-off of 
1.5 (Supplementary Table 4). Volcano plots of protein 
expression data were created using the plot function 
in R. Gene set testing of significantly up and down 
regulated proteins was performed using the Functional 
Annotation Clustering tool of DAVID version 6.8 [32, 
33] (Supplementary Table 5A-5B). As there is a paucity 
of functional information is available for the Tasmanian 
devil, protein lists were analysed using the Homo sapiens 
species database, with medium stringency. Protein-protein 
interactions between up regulated proteins were identified 
using the STRING Database version 10.5 [34]. Only 
interactions predicted with high confidence (interaction 
score ≥ 0.700) were included in the analysis.
CONCLUSIONS 
In this study, we have analysed the response 
of DFT1 cells to imiquimod at the transcriptome 
and proteome level in order to improve the current 
understanding of the direct anti-tumor effects of this 
small molecule in cancer. This analysis has demonstrated 
that imiquimod disrupts cellular homeostasis, leading to 
a myriad of molecular changes that are consistent with 
activation of oxidative and ER stress responses (Figure 
7). These changes included positive regulation of PERK, 
an attenuator of translation at the ER, which likely altered 
protein production to favour other regulated pro-survival 
mechanisms such as cell cycle arrest and autophagy. 
Attenuation of normal protein translation by PERK could 
have also lead to the negative regulation of tumourigenic 
pathways, perhaps rendering the cells more susceptible 
to apoptosis. Lastly, a range of pro- and anti-apoptotic 
genes involved in ER and oxidative stress responses were 
also positively regulated in our study, suggesting that 
the interaction of stress pathways controls the onset of 
apoptosis in the treated cells. As genes associated with ER 
stress responses were positively regulated across multiple 
DFT1 cell lines in our study, and within human cell lines in 
previous studies, the stress-mediated pathways that were 
regulated in our study may pose as potential drug targets 
for enhancement of the direct effects of imiquimod during 
cancer therapy. This study is the first comprehensive 
transcriptome and proteome analysis of any imiquimod-
treated tumor cell, and is the first proteomic analysis of 
any cell type of Tasmanian devil origin. Findings from 
this analysis will allow for improved mechanistic use of 
imiquimod as a cancer immunotherapy in both human and 
Tasmanian devil cancer trials..
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